1. Ekelund U, Ward HA, Norat T et al. Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC). Am J Clin Nutr 2015; 101(3): 613–621. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.114.100065>.
2. Pedersen BK. Body mass index-independent effect of fitness and physical activity for all-cause mortality. Scand J Med Sci Sports 2007; 17(3): 196–204.
3. Pedersen BK. Muscles and their myokines. J Exp Biol. 2011; 214(Pt 2): 337–346.
4. Pedersen BK. The diseasome of physical inactivity – and the role of myokines in muscle – fat cross talk. J Physiol 2009; 587(Pt 23): 5559–5568.
5. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343–1350.
6. Nocon M, Hiemann T, Muller-Riemenschneider F et al. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 2008; 15(3): 239–246.
7. Wolin KY, Yan Y, Colditz GA et al. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009; 100(4): 611–616.
8. Monninkhof EM, Elias SG, Vlems FA et al. Physical activity and breast cancer: a systematic review. Epidemiology 2007; 18(1): 137–157.
9. Paffenbarger RS Jr, Lee IM, Leung R. Physical activity and personal characteristics associated with depression and suicide in American college men. Acta Psychiatr Scand Suppl 1994; 377: 16–22.
10. Rovio S, Kareholt I, Helkala EL et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol 2005; 4(11): 705–711.
11. Goldstein MS. Humoral nature of the hypoglycemic factor of muscular work. Diabetes 1961; 10: 232–234.
12. Pedersen BK, Steensberg A, Fischer C et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 2003; 24(2–3): 113–119.
13. Asmussen E. Ventilation at transition from rest to exercise. Acta Physiol Scand 1973; 89(1): 68–78.
14. Mohr T, Andersen JL, Biering-Sorensen F et al. Long-term adaptation to electrically induced cycle training in severe spinal cord injured individuals. Spinal Cord 1997; 35(1): 1–16. Erratum in Spinal Cord 1997; 35(4): 262.
15. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharmacol Sci 2014; 125(2): 125–131.
16. Pedersen BK. Muscle as a secretory organ. Compr Physiol 2013; 3(3): 1337–1362.
17. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387(6628): 83–90.
18. Barra NG, Reid S, MacKenzie R et al. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring) 2010; 18(8): 1601–1607.
19. Spangenburg EE, Booth FW. Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(-/-) mouse. Cytokine 2006; 34(3–4): 125–130.
20. Kurek J, Bower J, Romanella M et al. Leukaemia inhibitory factor treatment stimulates muscle regeneration in the mdx mouse. Neurosci Lett 1996; 212(3): 167–170.
21. Sakuma K, Watanabe K, Sano M et al. Postnatal profiles of myogenic regulatory factors and the receptors of TGF-beta 2, LIF and IGF-I in the gastrocnemius and rectus femoris muscles of dy mouse. Acta neuropathol 2000; 99(2): 169–176.
22. Hamrick MW, McNeil PL, Patterson SL. Role of muscle-derived growth factors in bone formation. J Musculoskelet Neuronal Interact 2010; 10(1): 64–70.
23. Liang H, Pun S, Wronski TJ. Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology 1999; 140(12): 5780–5788.
24. Wu Y, Yakar S, Zhao L et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002; 62(4): 1030–1035.
25. Nonogaki K, Fuller GM, Fuentes NL et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136(5): 2143–2149.
26. van Hall G, Steensberg A, Sacchetti M et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003; 88(7): 3005–3010.
27. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88(4): 1379–1406.
28. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev 2006; 12: 6–33.
29. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278(46): 45777–45784.
30. Kim HJ, Higashimori T, Park SY et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004; 53(4): 1060–1067.
31. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24(12): 5434–5446.
32. Carey AL, Steinberg GR, Macaulay SL et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006; 55(10): 2688–2697.
33. Febbraio MA, Hiscock N, Sacchetti M et al. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53(7): 1643–1648.
34. Wallenius V, Wallenius K, Ahren B et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8(1): 75–79.
35. Ellingsgaard H, Ehses JA, Hammar EB et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 2008; 105(35): 13163–13168.
36. Ellingsgaard H, Hauselmann I, Schuler Bet al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.. Nat Med 2011; 17(11): 1481–1489.
37. Svacina S. Incretin therapy and the metabolic syndrome. Vnitř Lék 2011; 57(4): 417–421.
38. Nieman DC, Nehlsen-Cannarella SL, Fagoaga OR et al. Influence of mode and carbohydrate on the cytokine response to heavy exertion. Med Sci Sports Exerc 1998; 30(5): 671–678.
39. Starkie RL, Rolland J, Angus DJ et al. Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running. Am J Physiol Cell Physiol 2001; 280(4): C769-C774.
40. Febbraio MA, Pedersen BK. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 2005; 33(3): 114–119.
41. Lavoie ME, Rabasa-Lhoret R, Doucet E et al. Association between physical activity energy expenditure and inflammatory markers in sedentary overweight and obese women. Int J Obes (Lond) 2010; 34(9): 1387–1395.
42. Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic inflammation. Clin Chim Acta 2010; 411(11–12): 785–793.
43. Pedersen BK. A muscular twist on the fate of fat. N Engl J Med 2012; 366(16): 1544–1545.
44. Ginter E, Simko V. Recent data on obesity research: beta-aminoisobutyric acid. Bratisl Lek Listy 2014; 115(8): 492–493.
45. Bostrom P, Wu J, Jedrychowski MP et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481(7382): 463–468.
46. Domouzoglou EM, Maratos-Flier E. Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. Am J Clin Nutr 2011; 93(4): 901S-905S.
47. Hojman P, Brolin C, Gissel H et al. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PloS one 2009; 4(6): e5894. Dostupné z DOI: <http://doi: 10.1371/journal.pone.0005894>.